Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(04): 461-462
DOI: 10.4103/ijmpo.ijmpo_210_19
Editorial Commentary

First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer

Authors

  • Vanita Noronha

    Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

  • Prashant Mehta

    Department of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Faridabad, Haryana

  • Prabhat Singh Malik

    Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

  • Amol Patel

    Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India

Financial support and sponsorship Nil.
Further Information
Also available at
  Permissions and Reprints
Preview

Although immune checkpoint blockers (ICBs) were discovered in the 1990s, the initial reports of their efficacy in non-small-cell lung cancer (NSCLC) came through in 2012, when nivolumab (BMS-936558) showed responses in a Phase 1 study. From then on, there has been a constant flow of data pertaining ICBs in a multitude of previously treated malignancies.

ICBs have completely transformed care for untreated advanced NSCLC and now have entered the first-line therapeutic armamentarium based on convincing data. An encouraging update of Keynote-001 presented at the 2019 American Society of Clinical Oncology meeting showed that 23.2% overall and 29.6% of patients with a programmed death ligand (PD-L1) staining of >50% treated with pembrolizumab (P) upfront were alive at 5 years. We will be looking at some of the landmark trials of immunotherapy in treatment-naive NSCLC in relation to common clinical situations.



Publication History

Received: 15 October 2019

Accepted: 03 January 2020

Article published online:
03 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India